https://sciprofiles.com/profile/421228?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name
Dr. Díaz received his M.Sc. and Ph.D. (Chemistry) in 1988 and 1993 from the Universidad Complutense de Madrid, working at Centro de Investigaciones Biológicas Margarita Salas (CIB–MS)(Madrid) and Daresbury Laboratory (Warrington, UK), in the biological and structural mechanism of action for the antitumoral drugs paclitaxel and docetaxel. Following a postdoctoral stay at Katolieke Universiteit Leuven (Belgium) (1994–1998), in which he studied the biochemistry of ras-p21 oncogene activation, he returned to CIB–MS as an assistant researcher. In 2001, he founded his research group focused on the pharmacology of tubulin, which has produced more than 250 research publications. His group has discovered three of the seven tubulin druggable sites (laulimalide/peloruside, maytansine, gatorbulin). Since 2008, he has been a senior staff scientist and, from 2021, has been the head of a unit on the development of new biologic, immunological, and chemical therapeutics for the global health of CIB–MS.
https://sciprofiles.com/profile/421228?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name
Dr. Díaz received his M.Sc. and Ph.D. (Chemistry) in 1988 and 1993 from the Universidad Complutense de Madrid, working at Centro de Investigaciones Biológicas Margarita Salas (CIB–MS)(Madrid) and Daresbury Laboratory (Warrington, UK), in the biological and structural mechanism of action for the antitumoral drugs paclitaxel and docetaxel. Following a postdoctoral stay at Katolieke Universiteit Leuven (Belgium) (1994–1998), in which he studied the biochemistry of ras-p21 oncogene activation, he returned to CIB–MS as an assistant researcher. In 2001, he founded his research group focused on the pharmacology of tubulin, which has produced more than 250 research publications. His group has discovered three of the seven tubulin druggable sites (laulimalide/peloruside, maytansine, gatorbulin). Since 2008, he has been a senior staff scientist and, from 2021, has been the head of a unit on the development of new biologic, immunological, and chemical therapeutics for the global health of CIB–MS.